Oncotarget

Research Papers:

Strong Inhibition of Xenografted Tumor Growth by Low-Level Doses of [32P]ATP

Yulan Cheng, Jian Yang, Rachana Agarwal, Gilbert M. Green, Ron C. Mease, Martin G. Pomper, Stephen J. Meltzer and John M. Abraham _

PDF  |  HTML  |  Order a Reprint

Oncotarget. 2011; 2:461-466. https://doi.org/10.18632/oncotarget.289

Metrics: PDF 1485 views  |   HTML 2075 views  |   ?  


Abstract

Yulan Cheng1, Jian Yang1, Rachana Agarwal1, Gilbert M. Green2, Ron C. Mease2, Martin G. Pomper2, Stephen J. Meltzer1, John M. Abraham1

1 Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD 21287

2 Department of Radiology, Johns Hopkins School of Medicine, Baltimore, MD 21287

Keywords: xenografts, inhibition, nude mice

Received: June 3, 2011; Accepted: June 3, 2011; Published: June 5, 2011;

Correspondence:

Stephen J. Meltzer, e-mail:

John M. Abraham, e-mail:

Abstract

The ability of a potential human anti-cancer therapeutic agent to inhibit the growth of xenografted tumors in nude mice has been an established and accepted testing method for several decades. The current report shows that a single, low-level intravenous dose of [32P]ATP significantly inhibits the growth of established xenografted tumors in nude mice.  This inhibitory effect becomes appreciable very rapidly, within only five days post-injection and the low dose demonstrates little or no toxicity in the mice. Surprisingly, a narrow dose window of optimum effectiveness is seen, whereby either decreasing or increasing the [32P]ATP dose results in far less growth inhibition. Thus, the intravenous systemic injection of [32P]ATP may represent a simple, potent method to target and inhibit primary human tumors and malignant lesions.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 289